Leading new oncology start-up establishes its research and development base at the Princess Margaret Cancer Research Tower
Toronto, February 10, 2021 — Following a very successful 2020, UHN spin-out Treadwell Therapeutics continues its global growth with the recent opening of its 9000 square-foot research and development facility in February 2021 at Toronto’s University Health Network, Canada’s leading research hospital. Treadwell’s footprint in Toronto is an important addition to Ontario’s emerging biotechnology cluster with the hire of 17 employees and a focus on current programs involving small molecules, biologics, TCR-based cell therapy and novel platforms for target discovery and validation.
“Treadwell is a company with global aspirations and deep roots in Toronto,” said Dr. Michael W. Tusche, co-CEO. “We see a tremendous talent pool and favourable environment that allows us to grow our team locally and to continue to contribute to the life science innovation ecosystem in Canada.”
“We are pleased to see Treadwell begin operations right here in Toronto,” says Mark Taylor, Director, Technology Development & Commercialization, UHN. “We consider it vitally important to support our companies, and we have shown that proximity creates new opportunities for collaboration that keeps companies in Canada.”
About Treadwell Therapeutics
Treadwell Therapeutics is a clinical-stage oncology company exploiting cancer cells’ vulnerabilities to develop first-in-class and best-in-class therapeutics to address unmet needs in patients with cancer.
The Company’s robust, internally developed clinical pipeline includes a first-in-class PLK4 kinase inhibitor, CFI-400945 and a potentially best in class TTK inhibitor, CFI-402257 ready for Phase 2, and CFI-402411, an oral immunomodulatory kinase inhibitor with activity toward HPK1 in Phase 1/2 studies. For more information, please visit www.treadwelltx.com. For general inquiries please email: email@example.com.